Novartis AG has secured conditional approval in Europe for its spinal muscular atrophy therapy Zolgensma and has hit the ground running with access programs for the closely-watched gene therapy.
Just shy of two months after a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human...